These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26432047)

  • 1. Chemotherapy plus ponatinib: a new standard for Ph-positive ALL?
    Thomas X
    Lancet Oncol; 2015 Nov; 16(15):1451-1453. PubMed ID: 26432047
    [No Abstract]   [Full Text] [Related]  

  • 2. Ponatinib for chronic myeloid leukemia.
    Goldman JM
    N Engl J Med; 2012 Nov; 367(22):2148-9. PubMed ID: 23190226
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponatinib given for advanced leukemia relapse after allo-SCT.
    Hirschbuehl K; Rank A; Pfeiffer T; Slawik HR; Schlimok G; Kolb HJ; Schmid Ch
    Bone Marrow Transplant; 2015 Apr; 50(4):599-600. PubMed ID: 25581405
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.
    Jen WY; Jabbour E; Short NJ; Issa GC; Haddad FG; Jain N; Pemmaraju N; Daver NG; Masarova L; Borthakur G; Chien K; Garris R; Kantarjian HM
    Am J Hematol; 2024 Nov; 99(11):2229-2232. PubMed ID: 39194286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponatinib circumvents FGF2-driven resistance to imatinib in CML.
    Cancer Discov; 2014 Mar; 4(3):OF10. PubMed ID: 24596204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
    Shah NP
    Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660
    [No Abstract]   [Full Text] [Related]  

  • 8. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does ponatinib cross the blood-brain barrier?
    Abid MB; De Mel S
    Br J Haematol; 2017 Nov; 179(3):497-498. PubMed ID: 27352067
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ponatinib in Philadelphia chromosome-positive leukemias.
    Quintas-Cardama A
    N Engl J Med; 2014 Feb; 370(6):577. PubMed ID: 24499222
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia.
    Marchesi F; Salvatorelli E; Renzi D; Mengarelli A; Minotti G; Menna P
    Br J Haematol; 2019 Oct; 187(1):e15-e17. PubMed ID: 31368155
    [No Abstract]   [Full Text] [Related]  

  • 13. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan.
    Takahashi N; Kondo T; Ikari Y; Fukumoto Y; Hatake K; Masunari A; Nishibayashi S; Kageyama A; Fukuta Y; Tojo A
    Jpn J Clin Oncol; 2024 Aug; 54(8):930-938. PubMed ID: 38747937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with ponatinib for central nervous system relapse of Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
    Masuda K; Nakazato T; Nishiyama-Fujita Y; Ito C; Ogura S; Mizuno K; Kamiya T; Aisa Y; Mori T
    Intern Med J; 2019 Oct; 49(10):1332-1334. PubMed ID: 31602766
    [No Abstract]   [Full Text] [Related]  

  • 16. Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
    Shomali W; Redmond C; Bogati S; Zimmerman C; Visconte V; Tabarroki A; Kalaycio M; Tiu RV
    Leuk Lymphoma; 2016; 57(1):193-5. PubMed ID: 25942382
    [No Abstract]   [Full Text] [Related]  

  • 17. Ponatinib-induced neutrophilic panniculitis.
    Zhang M; Hassan KM; Musiek A; Rosman IS
    J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ponatinib in Philadelphia chromosome-positive leukemias.
    Cortes JE; Talpaz M; Kantarjian H
    N Engl J Med; 2014 Feb; 370(6):577. PubMed ID: 24499221
    [No Abstract]   [Full Text] [Related]  

  • 19. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Short NJ; Konopleva M; Kadia T; Kebriaei P; Daver N; Huang X; Masarova L; Cook R; Jain N; Jabbour E; Kantarjian H; Ravandi F
    Am J Hematol; 2021 Jul; 96(7):E229-E232. PubMed ID: 33780038
    [No Abstract]   [Full Text] [Related]  

  • 20. Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia.
    Tefferi A
    Hematol Oncol; 2018 Oct; 36(4):718-720. PubMed ID: 29901221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.